# Emmanuelle Coutanceau

> Emmanuelle Coutanceau is a Series A investor at Novo Holdings backing Biotechnology. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Novo Holdings](https://shizune.co/investors/profile/novo-a-s)
- Location: Copenhagen, Denmark
- Total investments: 10
- Last investment: Mar 2025
- Lead investor: 30%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/emmanuelle-coutanceau-9973007

Emmanuelle Coutanceau is a Series A investor at Novo Holdings in Copenhagen focused on Biotechnology and Health Care. Emmanuelle Coutanceau joined Omnes Capital's Venture Capital team in April 2007.She holds a degree in agronomic engineering from the ENSAR in Rennes, a PhD in Microbiology from Paris VII University and a specialized postgraduate degree in pharmaceutical management from the Paris ESCP-EAP Business School.From 2003 to 2006, at PasteurInstitute, Emmanuelle Coutanceau managed a fundamental research project on the immunosuppressive properties of a bacterial toxin. Her work led to several international scientific publications. In Omnes Capital, she has been actively involved in several investments. She currently serves as director on the board of Amakem, Complix, Arcarios and as observer on the board of FlexGen, Medisse, ERA Biotech and Complix.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 60% |
| Health Care | 3 | 30% |
| Medical | 2 | 20% |
| Life Science | 2 | 20% |
| Therapeutics | 2 | 20% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 50% |
| Series B | 2 | 20% |
| Grant | 1 | 10% |
| Series C | 1 | 10% |
| Funding Round | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 3 | 30% |
| France | 2 | 20% |
| Denmark | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Augustine Therapeutics | Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors and GABABR1a activators for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $83.9M | Series A | Mar 24, 2025 |  |
| Coave Therapeutics | Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases. | $32.9M | Series A | Jan 09, 2025 |  |
| Minervax | Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $23.4M | Series C | Dec 15, 2022 |  |
| Minervax | Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $52M | Series B | Dec 15, 2020 |  |
| Minervax | Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $4.8M | Grant | Jan 21, 2019 |  |
| Pherecydes Pharma | Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to itsouter membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria. | $2.7M |  | Mar 18, 2015 |  |
| Pherecydes Pharma | Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to itsouter membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria. | $2.1M | Series A | Dec 01, 2014 |  |
| Complix | Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins. | $13.2M | Series B | Jun 26, 2013 |  |
| Amakem | Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. Amakem's product pipeline is based on its unique ‘Localized Drug Action' platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducingside effects. | $19.7M | Series A | Sep 06, 2011 |  |
| Complix | Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins. | $2.2M | Series A |  |  |

10 of 10 investments shown.

## Co-investors
- [Sunstone Life Science Ventures](https://shizune.co/investors/profile/sunstone-capital-life-science) — VC Fund, 3 deals together
- [Adjuvant Capital](https://shizune.co/investors/profile/adjuvant-capital) — VC Fund, 2 deals together
- [Gemma Frisius Fund](https://shizune.co/investors/profile/gemma-frisius-fund) — VC Fund, 2 deals together
- [Industrifonden](https://shizune.co/investors/profile/industrifonden) — VC Fund, 2 deals together
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund, 2 deals together
- [Sanofi Ventures](https://shizune.co/investors/profile/sanofi-genzyme-bioventures) — VC Fund, 2 deals together

## About Novo Holdings

VC Fund · Hellerup, Denmark

Novo Holdings is a holding and investment firm that manages the assets of the Novo Nordisk Foundation. It is a life science investor with a diverse portfolio that includes equities, bonds, real estate, infrastructure, and private investments.

5 contacts available at Novo Holdings.

| Name | Title | Profile |
| --- | --- | --- |
| Emmanuelle Coutanceau | Partner Novo Seeds | https://shizune.co/investors/profile/emmanuelle-coutanceau |
| Thomas Dyrberg | Partner | https://shizune.co/investors/profile/thomas-dyrberg |
| Thomas Grotkjær | Investor & Principal | https://shizune.co/investors/profile/thomas-grotkj%C3%A6r |
| Abhijeet Lele | Senior Partner and Head of US Principal Investments | https://shizune.co/investors/profile/abhijeet-lele |
| Christopher Shen | Partner | https://shizune.co/investors/profile/christopher-shen |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Emmanuelle Coutanceau invest in?

Emmanuelle Coutanceau invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Emmanuelle Coutanceau last invest?

The most recent investment recorded for Emmanuelle Coutanceau closed in Mar 2025. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co